155 related articles for article (PubMed ID: 1722775)
21. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF.
Shichishima T; Terasawa T; Saitoh Y; Hashimoto C; Ohto H; Maruyama Y
Br J Haematol; 1993 Oct; 85(2):378-86. PubMed ID: 7506570
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
Seya T; Hara T; Matsumoto M; Akedo H
J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Bjørge L; Jensen TS; Matre R
Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
[TBL] [Abstract][Full Text] [Related]
24. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF).
Nicholson-Weller A; Russian DA; Austen KF
J Immunol; 1986 Aug; 137(4):1275-9. PubMed ID: 3090145
[TBL] [Abstract][Full Text] [Related]
25. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation.
Terstappen LW; Nguyen M; Lazarus HM; Medof ME
J Leukoc Biol; 1992 Dec; 52(6):652-60. PubMed ID: 1281489
[TBL] [Abstract][Full Text] [Related]
26. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
[TBL] [Abstract][Full Text] [Related]
27. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.
Tate CG; Uchikawa M; Tanner MJ; Judson PA; Parsons SF; Mallinson G; Anstee DJ
Biochem J; 1989 Jul; 261(2):489-93. PubMed ID: 2476116
[TBL] [Abstract][Full Text] [Related]
28. Structural and functional differences between decay-accelerating factor and red cell acetylcholinesterase.
Sugarman J; Devine DV; Rosse WF
Blood; 1986 Sep; 68(3):680-4. PubMed ID: 2427138
[TBL] [Abstract][Full Text] [Related]
29. Robust in vitro replication of Plasmodium falciparum in glycosyl-phosphatidylinositol-anchored membrane glycoprotein-deficient red blood cells.
Pattanapanyasat K; Walsh DS; Yongvanitchit K; Piyawatthanasakul N; Wanachiwanawin W; Webster HK
Am J Trop Med Hyg; 2003 Oct; 69(4):360-5. PubMed ID: 14640493
[TBL] [Abstract][Full Text] [Related]
30. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF.
Li B; Sallee C; Dehoff M; Foley S; Molina H; Holers VM
J Immunol; 1993 Oct; 151(8):4295-305. PubMed ID: 7691944
[TBL] [Abstract][Full Text] [Related]
31. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
32. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
[TBL] [Abstract][Full Text] [Related]
33. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
34. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
[TBL] [Abstract][Full Text] [Related]
35. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
36. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
Zalman LS; Wood LM; Frank MM; Müller-Eberhard HJ
J Exp Med; 1987 Feb; 165(2):572-7. PubMed ID: 2434597
[TBL] [Abstract][Full Text] [Related]
37. PIG-A, DAF and proto-oncogene expression in paroxysmal nocturnal haemoglobinuria-associated acute myelogenous leukaemia blasts.
Stafford HA; Nagarajan S; Weinberg JB; Medof ME
Br J Haematol; 1995 Jan; 89(1):72-8. PubMed ID: 7530480
[TBL] [Abstract][Full Text] [Related]
38. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.
Lederman MM; Purvis SF; Walter EI; Carey JT; Medof ME
Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4205-9. PubMed ID: 2471198
[TBL] [Abstract][Full Text] [Related]
39. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition.
Mason JC; Yarwood H; Sugars K; Morgan BP; Davies KA; Haskard DO
Blood; 1999 Sep; 94(5):1673-82. PubMed ID: 10477692
[TBL] [Abstract][Full Text] [Related]
40. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
Brooimans RA; van Wieringen PA; van Es LA; Daha MR
Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
